Acadia Pharma (NASDAQ: ACAD) reported Q2 EPS of ($0.27), $0.04 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $115.2 million versus the consensus estimate of $126.15 million.

GUIDANCE:

Acadia Pharma sees Q3 2021 revenue of $480-515 million, versus the consensus of $527.7 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.